{
  "source": "PA-Notification-Nuedexta.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1234-8\nProgram Prior Authorization/Notification\nMedications Nuedexta® (dextromethorphan/quinidine)\nP&T Approval Date 11/2017, 11/2018, 11/2019, 7/2020, 7/2021, 7/2022, 7/2023, 7/2024\nEffective Date 10/1/2024\n1. Background:\nNuedexta, a combination product containing dextromethorphan hydrobromide and quinidine\nsulfate, is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a\nvariety of neurologic conditions, and is characterized by involuntary, sudden, and frequent\nepisodes of laughing and/or crying. PBA episodes typically occur out of proportion or are\ninappropriate to the underlying emotional state. PBA is a specific condition, distinct from other\ntypes of emotional lability that may occur in patients with neurological disease or injury.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Nuedexta will be approved based on the following criterion:\na. Diagnosis of pseudobulbar affect\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Nuedexta will be approved based on the following criterion:\na. Documentation of positive clinical response to therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n4. References:\n1. Nuedexta [package insert]. Aliso Viejo, CA: Avanir Pharmaceuticals, Inc.; June 2019.\n© 2024 UnitedHealthcare Services, Inc.\n1\nProgram Prior Authorization/Notification – Nuedexta\nChange Control\n11/2017 New program.\n11/2018 Annu",
    " Aliso Viejo, CA: Avanir Pharmaceuticals, Inc.; June 2019.\n© 2024 UnitedHealthcare Services, Inc.\n1\nProgram Prior Authorization/Notification – Nuedexta\nChange Control\n11/2017 New program.\n11/2018 Annual review. Updated background section and references.\n11/2019 Annual review. Updated references.\n7/2020 Annual review. No changes.\n7/2021 Annual review. Added state mandate language.\n7/2022 Annual review. No changes.\n7/2023 Annual review. No changes.\n7/2024 Annual review. Updated initial authorization.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}